Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rocbrutinib + Obinutuzumab in R/R and T474 Mutant CLL/SLL
NCT06978088Phase 2Recruiting
- Start
- Jun 2025
- Primary completion
- Jun 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rocbrutinib in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL). Started Jun 2025; status: recruiting.
02
Drugs
rocbrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT06978088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06978088.